IMV Inc. (IMV.TO) Research

IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.

Market snapshot

Symbol
IMV.TO
Price
$1.12
Day change
0.00%
Market cap
$9.3M
P/E ratio
-0.18x
52-week range
0.62-13.1
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cloud DX Inc. (CDX.V)
  • CloudMD Software & Services Inc. (DOC.V)
  • Fire & Flower Holdings Corp. (FAF.TO)
  • LexaGene Holdings Inc. (LXG.V)
  • Orion Nutraceuticals Inc. (ORI.CN)
  • Reunion Neuroscience Inc. (REUN.TO)
  • RIV Capital Inc. (RIV.CN)
  • RYAH Group, Inc. (RYAH.CN)

Open IMV Inc. (IMV.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.